Isis Pharmaceuticals Shares Up 13.3% After Analyst Upgrade (ISIS)
Isis Pharmaceuticals (NASDAQ:ISIS) shot up 13.3% during mid-day trading on Friday after Canaccord Genuity raised their price target on the stock from $32.00 to $45.00, Stock Ratings News reports. Canaccord Genuity currently has a hold rating on the stock. Isis Pharmaceuticals traded as high as $61.30 and last traded at $57.88, with a volume of 5,957,741 shares trading hands. The stock had previously closed at $51.07.
A number of other analysts have also recently weighed in on ISIS. Analysts at Deutsche Bank initiated coverage on shares of Isis Pharmaceuticals in a research note on Wednesday, January 22nd. They set a “buy” rating and a $60.00 price target on the stock. Separately, analysts at Zacks reiterated a “neutral” rating on shares of Isis Pharmaceuticals in a research note on Tuesday, January 21st. They now have a $49.00 price target on the stock. Finally, analysts at Piper Jaffray upgraded shares of Isis Pharmaceuticals from an “underweight” rating to a “neutral” rating in a research note on Tuesday, November 26th. They now have a $38.00 price target on the stock, up previously from $25.00. One research analyst has rated the stock with a sell rating, five have issued a hold rating and four have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of $39.36.
The stock’s 50-day moving average is $47.7 and its 200-day moving average is $36.92. The company’s market cap is $6.848 billion.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.